NeoGenomics Stock Plunge: Exact Sciences Launches Cancerguard

NeoGenomics stock plummets as Exact Sciences unveils Cancerguard, a new early cancer detection blood test, intensifying competition in the cancer diagnostics market. Is this a buying opportunity amidst NeoGenomics' volatile year, marked by both a major patent win and a significant year-to-date stock decline? Find out how this new technology could reshape the future of cancer diagnostics and what it means for investors. Hosted on Acast. See acast.com/privacy for more information.